Found: 4
Select item for more details and to access through your institution.
Correction: ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer: Alexandra Leary.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer.
- Published in:
- BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12501-5
- By:
- Publication type:
- Article
KCNE4-dependent functional consequences of Kv1.3-related leukocyte physiology.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-94015-9
- By:
- Publication type:
- Article
Endocytosis: A Turnover Mechanism Controlling Ion Channel Function.
- Published in:
- Cells (2073-4409), 2020, v. 9, n. 8, p. 1833, doi. 10.3390/cells9081833
- By:
- Publication type:
- Article